3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Phase 2/3
1
Status
Terminated
1
Completed
1
Sponsor Class
INDUSTRY
2
OTHER
1
Study Type
Interventional
2
Sponsor
Cancer Type
Breast
2
Conditions
Breast Neoplasms
12
Neoplasm Metastasis
6
Glioblastoma
4
Triple Negative Breast Neoplasms
3
Brain Neoplasms
3
Pancreatic Neoplasms
2
Ovarian Neoplasms
2
Neoplasms
2
Hereditary Sensory and Autonomic Neuropathies
2
Carcinoma, Non-Small-Cell Lung
2
Treatment for Metastatic or Locally Advanced Cervical Cancer
1
Stomach Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
Recurrence
1
Pre-menopausal Breast Cancer
1
Non-Small Cell Lunch Cancer
1
Melanoma
1
Lymphoma, Non-Hodgkin
1
Lymphoma, Mantle-Cell
1
Lymphoma, Large B-Cell, Diffuse
1
Lymphoma, Follicular
1
Locally Advanced Solid Tumor
1
Leukemia, Myeloid, Acute
1
Hematologic Neoplasms
1
Head and Neck Neoplasms
1
Gliosarcoma
1
Esophageal Neoplasms
1
Endometrial Neoplasms
1
Colorectal Neoplasms
1
Colonic Neoplasms
1
Interventions
Fulvestrant
9
Alpelisib
6
Letrozole
4
serabelisib
3
ribociclib
3
palbociclib
3
duvelisib
3
berzosertib
3
Paclitaxel
3
PX-866
3
Cetuximab
3
sapanisertib
2
pembrolizumab
2
parsaclisib
2
binimetinib
2
Topotecan
2
NVP-BKM120
2
Irinotecan
2
Gemcitabine
2
venetoclax
1
tipifarnib
1
talazoparib
1
sotorasib
1
ruxolitinib
1
olaparib
1
obinutuzumab
1
niraparib
1
lorlatinib
1
liposomal doxorubicin
1
gedatolisib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
INDUSTRY
×
Hereditary Sensory and Autonomic Neuropathies
×
NVP-BKM120
×
Clear all
NCT01633060
2019-01-30
BELLE-3
Novartis
Phase 3
Terminated
432 enrolled
20 charts
NCT01572727
2017-03-09
BELLE-4
Novartis
Phase 2/3
Completed
416 enrolled
11 charts